Skip to main content
. 2019 Jun 20;8(6):619. doi: 10.3390/cells8060619

Table 2.

hPGDS inhibitors and their cellular targets, effective concentrations and doses, and experimental settings reported in literature.

Inhibitor Chemical Structure Company Cell Type/Disease Concentration Ref.
HQL-79 graphic file with name cells-08-00619-i001.jpg Cayman Chemicals BMDM, eosinophils;
OVA-induced lung inflammation		 5–100 µM
10 mg/kg		 [29,33]
[28]
TFC-007 graphic file with name cells-08-00619-i002.jpg Tocris nasal blockage in guinea pigs 30 mg/kg [120]
HPGDS inhibitor I graphic file with name cells-08-00619-i003.jpg Cayman Chemicals basophils;
murine lupus model		 5 mg/kg [57]
TAS-204 graphic file with name cells-08-00619-i004.jpg Taiho Pharmaceutical Co. Ltd. nasal blockage in guinea pigs 15–30 mg/kg [119]
TAS-205 not reported Taiho Pharmaceutical Co. Ltd. Duchenne‘s muscular dystrophy (Phase I) 1.67–13.33 mg/kg/dose [136]
KMN-698 not reported Sanofi Aventis
(Cayman Chemicals)		 ILC-2 100 nM [84]
ZL-2102 not reported Zai Lab Pty. Ltd./Sanofi healthy males
(Phase I)		 5 to 750 mg [135]

BMDM—bone marrow-derived macrophage; ILC—innate lymphoid cells; OVA—ovalbumin.